Change of Hospitalization Status Among Patients With End-Stage Kidney Disease Before and After Receiving Chronic Hemodialysis

doi:10.21203/rs.3.rs-443055/v1

Download PDF

Research Article

Change of Hospitalization Status Among Patients With End-Stage Kidney Disease Before and After Receiving Chronic Hemodialysis

https://doi.org/10.21203/rs.3.rs-443055/v1

This work is licensed under a CC BY 4.0 License

Version 1

posted 29 Apr, 2021

You are reading this latest preprint version

Background:

Compared with other diseases, end-stage kidney disease (ESKD) carries a greater risk of comorbidities including diabetes and anemia and has a higher hospital admission rate. The cause of hospital admission appears to be a common factor affecting the prognosis of patients with ESKD. Therefore, this study conducted a retrospective cohort analysis on all patients diagnosed with ESKD and receiving hemodialysis, investigating whether the type of their diagnosis for hospital admission changed before and after they started hemodialysis.

Methods:

This study recruited 592 patients with ESKD who received hemodialysis at any period between January 2005 and November 2017 and had been assigned the International Classification of Diseases Ninth Revision Clinical Modification (ICD-9-CM) code for ESKD. The patients’ demographic data and hospitalization status one year before and two years after they received hemodialysis were analyzed. A McNemar test was conducted to analyze the diagnostic changes from before to after hemodialysis in patients with ESKD.

Results:

The study’s sample of patients with ESKD comprised more women (51.86%) than men and had an average age of 67.15 years. The numbers of patients admitted to hospital for the following conditions all decreased significantly after they received hemodialysis: type 2 (non-insulin-dependent and adult-onset) diabetes; native atherosclerosis; urinary tract infection; gastric ulcer without mention of hemorrhage, perforation, or obstruction; pneumonia; reflux esophagitis; duodenal ulcer without mention of hemorrhage, perforation, or obstruction; and bacteremia. Most patients exhibited one or more of the following comorbidities: diabetes (n = 407, 68.75%), hypertension (n = 491, 82.94%), congestive heart failure (n = 161, 27.20%), ischemic heart disease (n = 125, 21.11%), cerebrovascular accident (n = 93, 15.71%), and gout (n = 96, 16.22%). An analysis of variance (ANOVA) indicated that changes in the ICD-9-CM codes for native atherosclerosis, urinary tract infection, pneumonia, and hyperkalemia were associated with age. Patients who developed pneumonia before or after they received hemodialysis tended to be older (range: 69–70 years old).

Conclusions:

This study investigated the causes of hospital admission among patients with ESKD one year before and two years after they received hemodialysis. This study results revealed hypertension to be the most common comorbidity. Regarding cause of admission, pneumonia was more prevalent in older than in younger patients. Moreover, changes in the ICD-9-CM codes of native atherosclerosis, urinary tract infection, pneumonia, and hyperkalemia were significantly correlated with age. Therefore, when administering comprehensive nursing care and treatment for ESKD, clinicians should not focus only on comorbidities but also consider factors (e.g., age) that can affect patient prognosis.

Urology & Nephrology

End-Stage Kidney Disease

End-Stage Renal Disease

Hospitalizations

Chronic Hemodialysis

End-stage Kidney disease (ESKD) has been a global public health problem over the past few decades [1, 2], and research teams around the globe have investigated ESKD’s causes and effects [3, 4]. Taiwan has higher incidence and prevalence rates of ESKD that do developed countries. Compared with other diseases, ESKD results in a relatively large healthcare burden and high hospital admission rate [5, 6]. According to the 2016 Annual Data Report published by the United States Renal Data System, admissions and readmissions to hospitals constituted the major burden to patients with ESKD, where the average patient with ESKD is admitted to hospital twice a year [7]. The high medical cost of ESKD treatment has been an increasing burden on Taiwan’s healthcare system. According to the National Health Research Institutes’ 2018 Annual Report on Kidney Disease in Taiwan, the 2016 incidence and prevalence rates of ESKD requiring dialysis were 493 and 3,392 people per million population, respectively; these figures equate to an annual increase of 1.9% over the previous three years. The admission rate per 1,000 dialysis patients increased from 923 admissions in 2000 to 1,015 admissions in 2016, indicating the increase in admission rate among patients receiving dialysis [8], and this increasing trend was primarily attributable to the admission of patients with ESKD. Accordingly, reducing the admission rate of and monitoring dialysis quality among patients with ESKD have become urgent issues for health care policy makers in Taiwan and abroad.

Compared with other diseases, ESKD has a higher mortality rate and involves a greater utilization of outpatient, emergency, and inpatient services due to its more complex clinical comorbidities (e.g., diabetes, heart diseases, anemia, cardiovascular diseases [stroke and peripheral vascular disease], lower albumin levels, and lower hematocrits) and higher risks of stroke, myocardial infarction, congestive heart failure, infectious disease, and sepsis [3, 9, 10]. Patients with ESKD are most burdened by admissions and readmissions, which become more frequent and severe as the disease progresses [5]. Observational studies conducted by a single medical institution or health maintenance organization have also demonstrated that patients with ESKD have a high burden of comorbidities [11]. In Taiwan, a 2016 survey of the prevalence rate of comorbidities in dialysis patients revealed that the top three comorbidities were as follows (percentage of all dialysis patients with the comorbidity written in parentheses): hypertension (83.3%), cardiovascular diseases (57.1%), and diabetes (50.4%).

The early determination of the hospitalization risk among patients with ESKD potentially reduces hospital admissions [12]. Studies have noted that in patients with ESKD, (1) patient condition and hospitalization rate are positively correlated and (2) the frequency and cause of hospital admissions affect ESKD prognosis [7, 13]. Studies on patients with ESKD have mostly focused on trends for admission and death rate in the first year of dialysis; these studies have rarely compared patient status before and after they received dialysis [5]. This study conducted a retrospective cohort analysis on all patients diagnosed with ESKD and receiving hemodialysis, investigating whether the type of their diagnosis for hospital admission changed before and after they started hemodialysis.

Ethics statement

This study has been approved by the Institutional Review Board Committee, En Cku Kong Hospital (reference number: ECKIRB1061202), and all experimental methods in this study conformed to the Declaration of Helsinki. Considering the low-risk nature of this study and its retrospective research design, the institutional review board, En Cku Kong Hospital requirements regarding patient informed consent were waived.

Data collection

This study collected data from the electronic medical records of patients with ESKD and from the dialysis patient database Taiwan Society of Nephrology: Kidney Dialysis, Transplantation (TSN-KiDiT). The Taiwan Society of Nephrology–Kidney Transplantation (TSN-KiDiT) database, having received reports from dialysis centers in Taiwan since 1997, integrates all medical records of patients with ESRD in Taiwanese hospitals and dialysis clinics who have required chronic hemodialysis. The data in TSN-KiDiT include demographic statistics, related diseases, date of first dialysis treatment, type of dialysis, residual renal function, and laboratory data of all patients receiving dialysis in Taiwan. This study collected annual reports of dialysis facilities including dialysis dose, treatment quality, laboratory data, and clinical results. Because the TSN-KiDiT facilitates access to existing patient data systems, this study collected all the medical records of patients with ESKD from it. A teaching hospital in Taiwan was the study site, and this study conducted a retrospective analysis on the dialysis data of 1873 patients with ESKD who received hemodialysis at this hospital at any period between January 2005 and November 2017. This study aimed to investigate whether the patients were assigned different International Classification of Diseases Ninth Revision Clinical Modification (ICD-9-CM) codes one year before versus two years after they received hemodialysis. Patients were included if they satisfied all of the following criteria: assigned the ICD-9-CM code for ESKD, aged 20 years or older, received hemodialysis, and had been hospitalized only in the teaching hospital. Accordingly, this study excluded 37 patients who had received either peritoneal dialysis for a long time or a kidney transplant; 62 patients who had no record of hospitalization; 35 patients who had started their hemodialysis since 2000; 59 patients whose data did not satisfy the inclusion criteria (one year before and two years after the hemodialysis); 445 patients whose follow-up data spanned shorter than the inclusion criteria (hemodialysis data for <2 years); 244 patients with a hospitalization record only for before their hemodialysis; and 399 patients (1) who had a hospitalization record only for after their hemodialysis, (2) who had a period of less than two years when their hemodialysis began and ended, and (3) who had been transferred between hospitals. Finally, 592 patients were recruited as participants (Fig. 1).

All diagnoses of ESKD involved a nephrologist and were based on the 2012 Kidney Disease Improving Global Outcome guidelines; the nephrologist evaluated the disease condition, confirmed the diagnosis, and determined the stage of chronic kidney disease according to the cause, glomerular filtration rate (GFR), and albuminuria category (CGA)[14] . All recruited patients in the present study were in the fifth stage of chronic kidney disease, having a GFR <15 ml/min/1.73m²[15].

This study collected the demographic data of patients with ESKD and their hospitalization data for one year before and two years after they received hemodialysis. The demographic and clinical data comprised age, sex, primary disease category, comorbidities, and reason for hospitalization. ICD-9-CM codes were used to record all primary and secondary diagnoses of patients with ESKD in the hospitalization data files. The recruited patients were assigned a total of 2995 ICD-9-CM diagnosis codes, 1% of which (100 codes) were retained in the study for analysis. Hemodialysis quality indices were established according to the On-Site Inspection Standards for Hemodialysis and Peritoneal Dialysis Practices and the clinical indices in the dialysis database published by the Taiwan Society of Nephrology [8, 16]. Six comorbidities (ICD-9-CM) were analyzed in this study: diabetes, hypertension, congestive heart failure, ischemic heart disease, cerebrovascular accident, and gout [8, 16-18].

Statistical analysis

The McNemar test employed in this study is a simple and common method used for binary matched-pairs data. This test can be used in longitudinal observational research, and it involves a 2 × 2 contingency table for testing the correlation between randomly paired variables [19-21]. This study first used the McNemar test to evaluate how the 100 primary and secondary diagnoses changed before versus after the patients received hemodialysis. The significance level was set at 0.05. Consulting the literature and considering which diagnoses significantly differed between before and after hemodialysis, this study selected 11 reasons for hospitalization: diabetes; essential hypertension; anemia; native atherosclerosis; urinary tract infection; gastric ulcer without mention of hemorrhage, perforation, or obstruction (hereafter gastric ulcer); pneumonia; reflux esophagitis; duodenal ulcer without mention of hemorrhage, perforation, or obstruction (hereafter duodenal ulcer); hyperkalemia; and bacteremia. The ICD-9-CM codes of these conditions were then used in a chi-square test to determine the association of the diagnosis changes with the six comorbidities and demographic variables [8, 22-25]. An analysis of variance (ANOVA) was then conducted to investigate the associations of age with those ICD-9-CM codes that exhibited significant differences before versus after hemodialysis. SAS for Windows version 9.4 (SAS Institute, Cary, NC, USA) was used to process and analyze the data.

Table 1 presents the distributions of the demographic data. A retrospective analysis was conducted on 592 patients who were assigned the ICD-9-CM code for ESKD at any time between January 2005 and November 2017. These patients comprised more women (51.86%) than men and had an average age of 67.15 years old (range: 24–94 years old, standard deviation = 12.29 years). The patients were segmented by when their hemodialysis began: ≤ 2005 (n = 97, 16.39%), 2006–2010 (n = 202, 34.12%), 2011–2013 (n =133, 22.47%), and > 2013 (n = 160, 27.03%). Three major primary disease categories were determined, namely “kidney disease”, “systemic disease”, and “others”. The systemic disease category accounted for the largest proportion of patients (n = 432, 72.97%). Most patients developed one or more of the following comorbidities: diabetes (n = 407, 68.75%), hypertension (n = 491, 82.94%), congestive heart failure (n = 161, 27.20%), ischemic heart disease (n = 125, 21.11%), cerebrovascular accident (n = 93, 15.71%), and gout (n = 96, 16.22%).

Table 2 presents the relationship of diagnoses (ICD-9-CM codes) and patients’ hospitalization status before and after they received hemodialysis. The McNemar test was used to examine how the 100 ICD-9-CM diagnosis codes [1, 8, 26, 27] changed before versus after hemodialysis. This study analyzed only 11 conditions that exhibited a statistical difference before versus after the treatment as follows: type 2 (non-insulin-dependent and adult-onset) diabetes (hereafter type 2 diabetes), essential hypertension, anemia, native atherosclerosis, urinary tract infection, gastric ulcer, pneumonia, reflux esophagitis, duodenal ulcer, hyperkalemia, and bacteremia. With regard to the causes of admission, the probabilities of being admitted for the following conditions decreased significantly after the patients received hemodialysis: type 2 diabetes, native atherosclerosis, urinary tract infection, gastric ulcer, pneumonia, reflux esophagitis, duodenal ulcer, and bacteremia. Comparing the numbers of patients admitted to the hospital for the 11 conditions before and after patients received hemodialysis, the result revealed a significant decrease from 65 admissions for type 2 diabetes (10.98%) before hemodialysis to 41 admissions (6.93%) after hemodialysis (p = 0.020); from 74 (12.50%) to 28 (4.73%) for native atherosclerosis (p < 0.001); from 90 (15.20%) to 58 (9.80%) for urinary tract infection (p = 0.009); from 91 (15.37%) to 34 (5.74%) for gastric ulcer (p < 0.001); from 113 (19.09%) to 58 (9.80%) for pneumonia (p < 0.001); from 68 (11.49%) to 40 (6.76%) for reflux esophagitis (p = 0.007); from 60 (10.14%) to 33 (5.57%) for duodenal ulcer (p = 0.005); and from 52 (8.78%) to 10 (1.69%) for bacteremia (p < 0.001). However, the probabilities of admission for essential hypertension, anemia, and hyperkalemia increased significantly after hemodialysis. The result revealed a significant increase in the number of admissions from 20 (3.38%) before hemodialysis to 112 (18.92%) after hemodialysis for essential hypertension (p < 0.001); from 76 (12.84%) to 124 (20.95%) for anemia (p < 0.001); and from 41 (6.93%) to 69 (11.66%) for hyperkalemia (p = 0.008).

Table 3 presents the relationship between age and the 11 ICD-9-CM codes that had exhibited significant difference before versus after hemodialysis. According to the ANOVA model, age was correlated with status changes in native atherosclerosis, urinary tract infection, pneumonia, and hyperkalemia. Younger patients were less likely to be admitted to the hospital for native atherosclerosis, urinary tract infection, and pneumonia before and after hemodialysis. Patients with hyperkalemia aged between 65 and 66 years and those who received hemodialysis were more likely to be admitted to the hospital for hyperkalemia (average age: 64 years old). Patients who had experienced urinary tract infection and hyperkalemia before they received hemodialysis tended to be older (average age: 70 years old). Older patients aged approximately 69-70 years old were more likely to develop pneumonia either before or after hemodialysis. Older patients were also more likely to have a urinary tract infection relative to their younger counterparts.

This study conducted a chi-square test to analyze the correlation between the six comorbidities and the changes in hospitalization diagnosis (ICD-9-CM) before versus after hemodialysis. Among patients diagnosed with type 2 diabetes, the probabilities of admission for diabetes, hypertension, and gout increased significantly after hemodialysis. Specifically, the number of admissions increased from 38 (9.34%) before hemodialysis to 50 (12.29%) after hemodialysis for diabetes (p < 0.001); from 35 (7.13%) to 52 (10.59%) for hypertension (p < 0.001); and from 5 (5.21%) to 9 (9.38%) for gout (p < 0.004). The number of patient admissions to the hospital for ischemic heart disease decreased significantly from 7 (5.60%) before hemodialysis to 6 (4.80%; Appendix 1) after hemodialysis. Among patients diagnosed with essential hypertension, the probability of admission for hypertension significantly decreased after hemodialysis; specifically, the number of admissions decreased from 99 (20.16%) before hemodialysis to 15 (3.05%) after hemodialysis for hypertension (p < 0.001; Appendix 2). Patients diagnosed with anemia exhibited nonsignificantly different number of hospital admissions for each of the comorbidities (i.e., diabetes, hypertension, congenstive heart failure, ischemic heart disease, cerebrovascular accident, and gout) after they received hemodialysis (Appendix 3). Among patients diagnosed with native atherosclerosis, the probabilities of admission for congestive heart failure and ischemic heart disease increased significantly after hemodialysis. Specifically, the number of admissions increased from 10 (6.21%) before hemodialysis to 25 (15.53%) after hemodialysis for congestive heart failure (p = 0.002) and from 14 (11.20%) to 22 (17.60%) for ischemic heart disease (p < 0.001; Appendix 4). Among patients diagnosed with urinary tract infection, the probabilities of admission for congestive heart failure and cerebrovascular accident increased significantly after hemodialysis. Specifically, the number of admissions increased from 21 (13.04%) before hemodialysis to 27 (16.77%) after hemodialysis for congestive heart failure (p = 0.007) and from 46 (9.22%) to 79 (15.83%) for cerebrovascular accident (p = 0.037; Appendix 5). Among patients diagnosed with gastric ulcer who received hemodialysis, the number of admissions decreased from 9 (9.38%) before hemodialysis to 8 (8.33%) after hemodialysis for gout (p = 0.049), whereas the number of admissions for cerebrovascular accident remained unchanged at 11 (11.83%; p = 0.043; Appendix 6). Among patients diagnosed with pneumonia, the number of admissions to the hospital for congestive heart failure and cerebrovascular accident increased, respectively, from 26 (16.15%) to 34 (21.12%; p < 0.001) and from 16 (17.20%) to 22 (23.66%; p = 0.004) from before to after hemodialysis (Appendix 7). Among patients diagnosed with reflux esophagitis, the number of admissions increased from 10 (10.75%) before hemodialysis to 15 (16.13%; p = 0.037) after hemodialysis for cerebrovascular accident; the number of admissions decreased from 15 (15.63%) to 11 (11.46%) for gout (p < 0.001; Appendix 8). Among patients diagnosed with duodenal ulcer, the number of admissions increased from 1 (1.86%) before hemodialysis to 21 (13.04%) after hemodialysis for congestive heart failure (p = 0.035; Appendix 9). Among patients diagnosed with hyperkalemia, the number of admissions decreased from 15 (12.00%) to 6 (4.80%) for congestive heart failure (p = 0.005; Appendix 10). Finally, among patients diagnosed with bacteremia, the number of hospital admissions increased from 5 (5.21%) before hemodialysis to 11 (11.46%) after hemodialysis for gout (p = 0.017; Appendix 11).

External arteriovenous shunts, invented in 1960, facilitate the application of hemodialysis in patients with ESKD. Hemodialysis has had a considerably improved prognosis, having undergone advances over the past 40 years. This improvement is mainly attributable to improved monitoring of medical quality, improved decision-making processes, more streamlined data analysis methods, and new dialysis technologies [8, 25, 28, 29]. The present study on patients with ESKD included patients’ demographic characteristics and medical history in its analysis of the reasons for admission one year before and two years after hemodialysis was received. This study employed a cross-sectional research design in analyzing data on six comorbidities and 12 causes of admission for 592 patients. This study’s sample female (307) and male (285) patients with approximately equal populations for all age groups. Among the 592 patients, hypertension was the most common comorbidity, which is consistent with findings in the literature; accordingly, hypertension was a prevalent disease in patients receiving hemodialysis.

Demographic statistics from the TSN-KiDiT were analyzed as categorical variables in the McNemar test for the cross-sectional analysis. According to cross-sectional datasets, this study revealed age and comorbidities as key variables affecting changes in the type of diagnosis for patients’ hospital admission before and after they started hemodialysis. Additionally, according to diagnoses in relation to age, the possibility of patients being admitted to the hospital for urinary tract infection, pneumonia, and hyperkalemia decreased significantly among all age groups. Cardiovascular diseases are considered the most influential risk factor for patients with ESKD during hospitalization. Most patients with ESKD have one or more comorbidities, and almost two-thirds of patients develop ESKD because of diabetes and hypertension; cardiovascular is also a prevalent comorbidity of ESKD [30]. Accordingly, the present study analyzed the six most common comorbidities of ESKD (prevalence rate written in parentheses), as follows: diabetes (68.75%), hypertension (82.94%), congestive heart failure (27.20%), ischemic heart disease (21.11%), cerebrovascular accident (21.11%), and gout (16.22%). Having multiple comorbidities increases the treatment burden (and, by implication, physical burden) on of patients, increasing the risk of noncompliance. Notably, anemia was found to be the second most common comorbidity of ESKD, echoing the finding of another study [31]. Among the patients receiving hemodialysis, the high prevalence of anemia as a comorbidity was attributable to the fact that ESKD increases the risk of anemia [32]. Moreover, the following 11 diseases may also increase the treatment burden and number of hospital admissions: type 2 diabetes, essential hypertension, anemia, native atherosclerosis, urinary tract infection, gastric ulcer, pneumonia, reflux esophagitis, duodenal ulcer, hyperkalemia, and bacteremia.

In terms of age, the older population exhibited a greatly increased prevalence of pathogenic comorbidities [33]. Three related studies have indicated that the incidence of ESKD increases with age. According to the present study’s results, younger participants (aged 65–66 years) were less prone to hospital admission due to atherosclerosis of the native coronary artery, urinary tract infection, or pneumonia. Participants who were admitted to hospitals for hyperkalemia after dialysis had an average age of 64 years. Those who had a urinary tract infection and hyperkalemia before dialysis tended to be older (average age: 70 years old). Finally, participants who developed pneumonia only before or after dialysis were also older (69–70 years on average), and urinary tract infection was more common among older participants.

A clinical epidemiological study reported that uremia in ESRD changed cell and humoral immunity, and hence, increased patients’ susceptibility to widespread infection. Although a low-grade urinary tract infection does not reduce renal functions, the recurrence of said infection can affect the progression of existent renal diseases, thereby causing renal functions to decline [34]. ESRD is a chronic inflammatory condition that increases patients’ susceptibility to widespread infection, and its comorbidities can lead to urinary tract infection due to conditions such as diabetes and incomplete bladder emptying [27].

ESKD is a prevalent condition, particularly in Taiwan, which has the highest incidence of ESKD and has performed the most renal replacement therapies worldwide. Prone to immunodeficiency, patients with ESKD have a higher risk of and mortality from infectious diseases than do those without ESKD [5, 6]. The high demand for inpatient treatment due to pneumonia and sepsis remains of concern.

Infections constitute a primary factor that drives admission and death among patients receiving dialysis [27]. For patients with ESKD, inpatient treatment for pneumonia is a common practice [26, 35]. With regard to the causes of admission, admissions for pneumonia were more common among older patients; specifically, patients who developed pneumonia before or after hemodialysis tended to be older (range: 69–70 years old). Compared with younger patients with ESKD, older patients cannot position themselves or walk on their own, which increase their risk of pneumonia during hospitalization [36]. The present study revealed a significant correlation between pneumonia and ESKD.

Common among patients receiving dialysis, acute nursing care and hospital admissions account for the largest proportion (approximately 40%) of the cost of ESKD treatment [7]. To enhance nursing care quality and resource use efficiency for patients with ESKD, countries should prioritize investigations into the causes or results of these patients’ hospital admissions. One study revealed a positive correlation between the health status and admission rate of patients with ESKD and that the frequency and cause of admission affected their prognosis. Typically, a general patient with ESKD is admitted to hospital twice annually on average, and the two leading causes for admission are cardiovascular events and infectious diseases [3, 37].

ESKD exhibits complex clinical comorbidities, and care for the disease is thus challenging. Such care involves the participation of not only a hemodialysis team but also other medical teams from various specializations (e.g., diabetes, ophthalmology, and neurology); it also involves the provision of health education on chronic kidney disease that is personalized according to the patient’s comorbidities, dialysis type, and lifestyle. Nursing care for ESKD is aimed at improving the patient’s quality of life, at arresting the deterioration of kidney functions, and at preventing the development of comorbidities. Therefore, such nursing care should be practiced according to the following foci: (1) improve patients’ understanding of the comorbidities of kidney diseases; (2) provide personalized health education (administered by kidney health educators) in accordance with the patient’s comorbidities; (3) communicate the proper health-seeking behaviors and the importance of regular follow-ups to patients to prevent patients from using over-the-counter or folk medicine and to reduce patient drop-outs from dialysis; (4) reduce the admission rate, which is realized by (4a) early contact with patients with ESKD, (4b) cross-team collaboration among medical professionals, and (4c) continual communication with caregivers and patients; (5) provide patients with the appropriate nutritional knowledge for ESKD and understand the dietary compliance of patients to foster appropriate dietary habits in patients. These nursing care foci facilitate comprehensive, continual, professional, and integrative medical care for patients to improve their quality of life.

The present study revealed correlations of comorbidities of ESRD with the duration and cause of hospital admission. It conducted comprehensive data collection on risk factors and comorbidities of ESRD and, with a retrospective design, followed up on the cause of hospital admission of patients with ESRD 1 year before they started dialysis and 2 years after dialysis. The study model involved investigating changes in 100 primary and secondary diagnoses of patients with ESKD before and after dialysis, which could aid the precise recording of patients’ renal functions and prognosis. The data used in this study are of high quality because they were collected from a large-scale renal registration system [38]. The study results highlight the need to control comorbidities associated with ESKD and affect clinical and research practice. By integrating test data on patients receiving dialysis, this study provides comprehensive information on patients with ESKD. Having made a breakthrough in investigating patients receiving dialysis, this study offers valuable insights that are conducive to analyzing epidemiological and relevant risk factors among Taiwanese patients receiving dialysis; thus, it will aid in the future prevention of renal diseases, enhance the survival of these patients, and reduce the incidence of associated comorbidities.

This study has several limitations. The first lies in its retrospective design and limited sample size. In this study’s retrospective analysis, patients with missing data and records were excluded. Second, the data were collected from the TSN-KiDiT, which lacked clinical indicators critical to the research topic; therefore, this study could not obtain information regarding the severity of certain diseases (e.g., blood pressure and the severities of diabetes and left ventricular hypertrophy). Additionally, other comorbidities, such as alcohol or substance dependence, have been reported to be associated with ESKD [22] , but they were not included in this study’s analysis. Considering the research context of this study, the lack of disease data can result in results for a disease to be underestimated, which yields the false conclusion that the disease is unrelated to ESKD. Third, the inclusion criteria in this study were patients with ESKD who received hemodialysis and had complete medical data one year before and two years after their hemodialysis. Therefore, patients whose medical data did not conform to the criteria were excluded; this constituted another limitation of this study. Furthermore, this study analyzed only data collected by one hospital. The sample comprised only patients in the hospital who met the inclusion criteria, and some variables may have been overlooked. Because this study focused on the hemodialysis data of only one hospital, this single-center characteristic limits the generalizability of the study results to patients with ESKD with various combinations of comorbidities from other hospitals. Therefore, prospective research involving a larger patient sample size is required to verify the present study’s findings.

This study investigated the causes of ESKD patients’ admissions to a hospital one year before and two years after they received hemodialysis. This study results show that (1) hypertension to be the most common comorbidity and (2) cardiovascular diseases to be the most influential risk factor for patients with ESKD during hospitalization. Most patients with ESKD exhibited one or more comorbidities, and two-thirds of them developed ESKD because of diabetes and hypertension. With regard to the causes of admission, pneumonia was more prevalent among older patients. Additionally, changes in the diagnosis codes of native atherosclerosis, urinary tract infection, pneumonia, and hyperkalemia were significantly correlated with age. Therefore, when administering comprehensive nursing care and treatment for ESKD, clinicians should not focus only on comorbidities but also consider factors (e.g., age) that can affect patient prognosis.

ESKD：End-Stage Kidney Disease

TSN-KiDiT：Taiwan Society of Nephrology: Kidney Dialysis, Transplantation

ICD-9-CM：International Classification of Diseases Ninth Revision Clinical Modification

KDIGO：Kidney Disease: Improving Global Outcomes

GFR：glomerular filtration rate

CGA：albuminuria categories

Ethics approval and consent to participate:

This study was approved by the experimental practices adopted conformed entirely to the Declaration of Helsinki. Institutional Review Board (reference number: ECKIRB106120), and the experimental practices adopted conformed entirely to the Declaration of Helsinki. Considering the low-risk nature of this study and its retrospective research design, the institutional review board, En Cku Kong Hospital requirements regarding patient informed consent were waived.

Consent for Publication:

NA/Not Applicable.

Availability of data and materials:

The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

Competing interests:

The authors declare no competing financial interests.

Funding:

The corresponding author is grateful to the Ministry of Science and Technology of the Republic of China (Taiwan) and the Linkou Chang Gung Memorial Hospital for financially supporting this research (Most-109-2410-H-182-009-MY3, and BMRPA19), respectively.

Authors’ contributions:

Data curation H-LL, P-HT, Y-TH, L-CL.

Formal analysis: H-LL, P-HT, Y-TH, S-WL, L-CL.

Funding acquisition: H-LL, P-HT, S-WL.

Investigation: H-LL, P-HT, Y-TH, S-WL.

Methodology: H-LL, Y-TH, S-WL.

Project administration: H-LL, P-HT, Y-TH, S-WL.

Resources: H-LL, P-HT, Y-TH, S-WL.

Software: H-LL, Y-TH.

Supervision: H-LL, P-HT, Y-TH, S-WL.

Validation: H-LL, P-HT, Y-TH, S-WL.

Visualization: H-LL, P-HT, Y-TH, S-WL.

Writing – original draft: H-LL, P-HT, Y-TH, S-WL.

Writing – review & editing: H-LL, P-HT, Y-TH, S-WL.

Acknowledgements:

The authors thank for En Chu Kong Hospital support for this study.

Collins AJ, Foley RN, Gilbertson DT, Chen S-C: The state of chronic kidney disease, ESRD, and morbidity and mortality in the first year of dialysis. Clinical Journal of the American Society of Nephrology 2009, 4(Supplement 1):S5-S11.
Zhang A-H, Cheng L-T, Zhu N, Sun L-H, Wang T: Comparison of quality of life and causes of hospitalization between hemodialysis and peritoneal dialysis patients in China. Health and quality of life outcomes 2007, 5(1):49.
Go AS, Chertow GM, Fan D, McCulloch CE, Hsu C-y: Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. New England Journal of Medicine 2004, 351(13):1296–1305.
Teo BW, Ma V, Xu H, Li J, Lee EJ, Group NCR: Profile of hospitalisation and death in the first year after diagnosis of end-stage renal disease in a multi-ethnic Asian population. Annals Academy of Medicine Singapore 2010, 39(2):79.
Metcalfe W, Khan I, Prescott G, Simpson K, Macleod AM: Hospitalization in the first year of renal replacement therapy for end-stage renal disease. Qjm 2003, 96(12):899–909.
Fried TR, O’Leary J, Towle V, Goldstein MK, Trentelange M, Martin DK: The effects of comorbidity on the benefits and harms of treatment for chronic disease: a systematic review. PLoS One 2014, 9(11):e112593.
2016 USRDS annual data report: Epidemiology of kidney disease in the United States
Hsu C-C WM-S, Hsiung CA, Hwang S-J, Lin Y-F, Hsu Y-H: Annual Report on Kidney Disease in Taiwan. Miaoli County: National Health Research Institutes 2019.
Longenecker JC, Coresh J, Klag MJ, Levey AS, Martin AA, Fink NE, Powe NR: Validation of comorbid conditions on the end-stage renal disease medical evidence report: the CHOICE study. Journal of the American Society of Nephrology 2000, 11(3):520–529.
Brophy DF, Daniel G, Gitlin M, Mayne TJ: Characterizing hospitalizations of end-stage renal disease patients on dialysis and inpatient utilization of erythropoiesis-stimulating agent therapy. Annals of Pharmacotherapy 2010, 44(1):43–49.
Mix T-CH, Peter WLS, Ebben J, Xue J, Pereira BJ, Kausz AT, Collins AJ: Hospitalization during advancing chronic kidney disease. American journal of kidney diseases 2003, 42(5):972–981.
Plantinga LC, Masud T, Lea JP, Burkart JM, O’Donnell CM, Jaar BG: Post-hospitalization dialysis facility processes of care and hospital readmissions among hemodialysis patients: a retrospective cohort study. BMC nephrology 2018, 19(1):186.
Usvyat LA, Kooman JP, van der Sande FM, Wang Y, Maddux FW, Levin NW, Kotanko P: Dynamics of hospitalizations in hemodialysis patients: results from a large US provider. Nephrology Dialysis Transplantation 2013, 29(2):442–448.
Andrassy KM: Comments on ‘KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease’. Kidney international 2013, 84(3):622–623.
Jha V, Garcia-Garcia G, Iseki K, Li Z, Naicker S, Plattner B, Saran R, Wang AY-M, Yang C-W: Chronic kidney disease: global dimension and perspectives. The Lancet 2013, 382(9888):260–272.
Wu M-S, Wu I-W, Shih C-P, Hsu K-H: Establishing a platform for battling end-stage renal disease and continuing quality improvement in dialysis therapy in Taiwan-Taiwan Renal Registry Data System (TWRDS). Acta Nephrologica 2011, 25(3):148–153.
Hazzan AD, Halinski C, Agoritsas S, Fishbane S, DeVita MV: Epidemiology and challenges to the management of advanced CKD. Advances in chronic kidney disease 2016, 23(4):217–221.
Keith DS, Nichols GA, Gullion CM, Brown JB, Smith DH: Longitudinal follow-up and outcomes among a population with chronic kidney disease in a large managed care organization. Archives of internal medicine 2004, 164(6):659–663.
Fagerland MW, Lydersen S, Laake P: The McNemar test for binary matched-pairs data: mid-p and asymptotic are better than exact conditional. BMC medical research methodology 2013, 13(1):91.
Kim S, Lee W: Does McNemar’s test compare the sensitivities and specificities of two diagnostic tests? Statistical methods in medical research 2017, 26(1):142–154.
Sun X, Yang Z: Generalized McNemar’s test for homogeneity of the marginal distributions. In: SAS Global forum: 2008; 2008: 1–10.
Krishnan M, Weinhandl ED, Jackson S, Gilbertson DT, Lacson Jr E: Comorbidity ascertainment from the ESRD Medical Evidence Report and Medicare claims around dialysis initiation: a comparison using US Renal Data System data. American Journal of Kidney Diseases 2015, 66(5):802–812.
Sood P, Kumar G, Nanchal R, Sakhuja A, Ahmad S, Ali M, Kumar N, Ross EA: Chronic kidney disease and end-stage renal disease predict higher risk of mortality in patients with primary upper gastrointestinal bleeding. American journal of nephrology 2012, 35(3):216–224.
Sakhuja A, Nanchal RS, Gupta S, Amer H, Kumar G, Albright RC, Kashani KB: Trends and outcomes of severe sepsis in patients on maintenance dialysis. American Journal of Nephrology 2016, 43(2):97–103.
Jenq C-C, Hung C-C, Juan K-C, Hsu K-H: The Effects of e-interventions on the Medical Outcomes of Hemodialysis Patients: A Retrospective Matched Patient Cohort Study. Scientific reports 2017, 7(1):1–11.
Huang S-T, Lin C-L, Chang Y-J, Sher Y-P, Wu M-J, Shu K-H, Sung F-C, Kao C-H: Pneumococcal pneumonia infection is associated with end-stage renal disease in adult hospitalized patients. Kidney international 2014, 86(5):1023–1030.
Dalrymple LS, Johansen KL, Chertow GM, Cheng S-C, Grimes B, Gold EB, Kaysen GA: Infection-related hospitalizations in older patients with ESRD. American Journal of Kidney Diseases 2010, 56(3):522–530.
Yeh J-Y, Wu T-H, Tsao C-W: Using data mining techniques to predict hospitalization of hemodialysis patients. Decision Support Systems 2011, 50(2):439–448.
Canaud B, Vienken J, Ash S, Ward RA: Hemodiafiltration to address unmet medical needs ESKD patients. Clinical Journal of the American Society of Nephrology 2018, 13(9):1435–1443.
Ceretta ML, Noordzij M, Luxardo R, De Meester J, Abad Diez JM, Finne P, Heaf JG, Couchoud C, Kramar R, Collart F: Changes in co-morbidity pattern in patients starting renal replacement therapy in Europe—data from the ERA-EDTA Registry. Nephrology Dialysis Transplantation 2018, 33(10):1794–1804.
Rottembourg J, Tilleul P, Deray G, Lafuma A, Zakin L, Mahi L, Wernli J: Cost of managing anemia in end-stage renal disease: the experience of five French dialysis centers. The European Journal of Health Economics 2015, 16(4):357–364.
Winkelmayer WC, Mitani AA, Goldstein BA, Brookhart MA, Chertow GM: Trends in anemia care in older patients approaching end-stage renal disease in the United States (1995–2010). JAMA internal medicine 2014, 174(5):699–707.
McDonald HI, Thomas SL, Nitsch D: Chronic kidney disease as a risk factor for acute community-acquired infections in high-income countries: a systematic review. BMJ open 2014, 4(4).
Naqvi SB, Collins AJ: Infectious complications in chronic kidney disease. Advances in chronic kidney disease 2006, 13(3):199–204.
Viasus D, Garcia-Vidal C, Cruzado JM, Adamuz J, Verdaguer R, Manresa F, Dorca J, Gudiol F, Carratala J: Epidemiology, clinical features and outcomes of pneumonia in patients with chronic kidney disease. Nephrology Dialysis Transplantation 2011, 26(9):2899–2906.
Guo H, Liu J, Collins AJ, Foley RN: Pneumonia in incident dialysis patients—the United States renal data system. Nephrology Dialysis Transplantation 2008, 23(2):680–686.
Dalrymple LS, Katz R, Kestenbaum B, De Boer IH, Fried L, Sarnak MJ, Shlipak MG: The risk of infection-related hospitalization with decreased kidney function. American journal of kidney diseases 2012, 59(3):356–363.
Lin Y-C, Hsu C-Y, Kao C-C, Chen T-W, Chen H-H, Hsu C-C, Wu M-S: Incidence and prevalence of ESRD in Taiwan renal registry data system (TWRDS): 2005–2012. Acta Nephrologica 2014, 28(2):65–68.

Table 1. Patient demographic characteristics

Variable	Categories	No. of patients	Percent
Year of hemodialysis initiation	<=2005	97	16.39
	2006-2010	202	34.12
	2011-2013	133	22.47
	>2013	160	27.03
Sex	Male	285	48.14
Sex	Female	307	51.86
Primary disease category	Kidney disease	144	24.32
	Systemic disease	432	72.97
	Others	16	2.70
Comorbidities Diabetes	No	185	31.25
Comorbidities Diabetes	Yes	407	68.75
Hypertension	No	101	17.06
Hypertension	Yes	491	82.94
Congestive heart failure	No	431	72.80
Congestive heart failure	Yes	161	27.20
Ischemic heart disease	No	467	78.89
Ischemic heart disease	Yes	125	21.11
Cerebrovascular accident	No	499	84.29
Cerebrovascular accident	Yes	93	15.71
Gout	No	496	83.78
Gout	Yes	96	16.22

Table 2. Hospitalization status before and after hemodialysis

	Category
	No before and No after		No before and Yes after		Yes before and No after		Yes before and Yes after
	Frequency	Percent	Frequency	Percent	Frequency	Percent	Frequency	Percent	P value
Type 2 diabetes	213	35.98	41	6.93	65	10.98	273	46.11	0.020
Essential hypertension	433	73.14	112	18.92	20	3.38	27	4.56	<.001
Anemia	316	53.38	124	20.95	76	12.84	76	12.84	<.001
Native atherosclerosis	423	71.45	28	4.73	74	12.50	67	11.32	<.001
Urinary tract infection	380	64.19	58	9.80	90	15.20	64	10.81	0.009
Gastric ulcer	443	74.83	34	5.74	91	15.37	24	4.05	<.001
Pneumonia	384	64.86	58	9.80	113	19.09	37	6.25	<.001
Reflux esophagitis	451	76.18	40	6.76	68	11.49	33	5.57	0.007
Duodenal ulcer	485	81.93	33	5.57	60	10.14	14	2.36	0.005
Hyperkalemia	466	78.72	69	11.66	41	6.93	16	2.70	0.008
Bacteremia	528	89.19	10	1.69	52	8.78	2	0.34	<.001

p values from McNemar test.

No before or No after: no hospital admission before hemodialysis, no hospital admission after hemodialysis.

No before and Yes after: no hospital admission before hemodialysis, hospital admission after hemodialysis.

Yes before and No after: hospital admission before hemodialysis, no hospital admission after hemodialysis.

Yes before and Yes after: hospital admission before hemodialysis, hospital admission after hemodialysis.

Table 3. Diagnoses in relation to different classifications of age

		No before and No after			No before and Yes after		Yes before and No after		Yes before and Yes after
Variables	Mean		Standard error (SE)	Mean		SE	Mean	SE		Mean	SE	P
Type 2 diabetes	68.44		13.63	64.02		12.72	66.88	12.03		66.94	10.96	0.082
Essential hypertension	67.76		12.49	63.70		8.96	65.60	12.38		66.52	10.02	0.214
Anemia	67.17		12.33	67.19		11.93	66.14	12.68		74.00	8.72	0.773
Native atherosclerosis	66.37		12.45	70.88		12.52	68.07	9.77		67.60	11.34	0.032*
Urinary tract infection	65.54		12.14	69.24		12.65	70.79	11.89		70.52	11.40	<.001**
Gastric ulcer	66.76		12.36	67.95		11.74	68.29	13.69		69.79	11.11	0.527
Pneumonia	66.03		12.26	69.19		12.44	69.69	11.97		68.65	11.47	0.025*
Reflux esophagitis	66.96		12.21	67.22		12.75	66.18	12.26		70.82	12.37	0.348
Duodenal ulcer	67.24		12.41	67.38		10.14	66.55	14.12		64.57	12.82	0.863
Hyperkalemia	66.86		12.19	64.07		13.15	70.23	11.71		70.38	13.22	0.040*
Bacteremia	66.72		12.25	70.67		11.50	71.30	14.06		70.50	27.58	0.101

p values from McNemar test.

No before or No after: no hospital admission before hemodialysis, no hospital admission after hemodialysis.

No before and Yes after: no hospital admission before hemodialysis, hospital admission after hemodialysis.

Yes before and No after: hospital admission before hemodialysis, no hospital admission after hemodialysis.

Yes before and Yes after: hospital admission before hemodialysis, hospital admission after hemodialysis.

*p < 0.05; **p < 0.01.

No competing interests reported.

appendix.docx

Download PDF

Version 1

posted 29 Apr, 2021

You are reading this latest preprint version

Change of Hospitalization Status Among Patients With End-Stage Kidney Disease Before and After Receiving Chronic Hemodialysis

Status:

Version 1

Abstract

Figures

Background

Methods

Results

Discussion

Conclusions

Abbreviations

Declarations

References

Tables

Additional Declarations

Supplementary Files

Status:

Version 1